In patients who receive rituximab, the simultaneous consideration of B cell reconstitution after depletion due to the therapy and ANCA-PR3 levels could fulfill the function of a biomarker for a GPA relapse, given that Cartin-Ceba et al. observed that all occurring relapses in the cohort under investigation were accompanied by an increase in B cells, preceded by an increase in ANCA-PR3 levels (129) (for a summary of biomarkers, see Tables 1, 2). This evidence concerns the gene PRTN3 and granulomatosis with polyangiitis.